As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Research cut their Q2 2026 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the ...

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...